Galapagos has applied its target discovery engine to identify novel drugable targets in Alzheimer’s disease (AD).

In February 2008, Galapagos’ target GT177 was confirmed in in vivo animal models, including knock-outs, to be a key regulator in the production of the amyloid ß peptides that are central to the pathogenesis of Alzheimer’s Disease. Galapagos is now actively looking for a licensee with the capability to develop a drug based on Galapagos’ intellectual property covering target GT177.

Contact Galapagos business development for more information.